Brokerages Set GH Research PLC (NASDAQ:GHRS) Price Target at $40.38

Shares of GH Research PLC (NASDAQ:GHRS) have been given a consensus rating of “Moderate Buy” by the eleven research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $40.3750.

Several research analysts recently issued reports on GHRS shares. HC Wainwright decreased their price objective on shares of GH Research from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Citizens Jmp reduced their target price on shares of GH Research from $42.00 to $39.00 and set a “market outperform” rating on the stock in a research report on Friday, May 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of GH Research in a research note on Tuesday, April 21st. Guggenheim set a $34.00 price target on shares of GH Research and gave the company a “buy” rating in a report on Tuesday, March 10th. Finally, Needham & Company LLC upped their price objective on GH Research from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, March 6th.

GH Research Price Performance

GHRS stock opened at $26.42 on Thursday. The business has a fifty day moving average price of $22.20 and a 200 day moving average price of $17.58. GH Research has a fifty-two week low of $11.32 and a fifty-two week high of $28.96. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of -28.72 and a beta of 1.28.

GH Research (NASDAQ:GHRS) last announced its earnings results on Thursday, May 14th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.04). On average, equities analysts expect that GH Research will post -1.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GH Research

Large investors have recently made changes to their positions in the company. JPMorgan Chase & Co. bought a new stake in GH Research during the 2nd quarter worth about $79,000. BNP Paribas Financial Markets lifted its holdings in GH Research by 165.4% in the second quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock valued at $207,000 after buying an additional 10,600 shares during the period. Osaic Holdings Inc. lifted its holdings in GH Research by 63.6% in the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after buying an additional 2,400 shares during the period. UBS Group AG boosted its stake in GH Research by 11.5% in the third quarter. UBS Group AG now owns 511,464 shares of the company’s stock valued at $7,314,000 after acquiring an additional 52,882 shares during the last quarter. Finally, Lynx1 Capital Management LP grew its holdings in GH Research by 27.5% during the 3rd quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company’s stock worth $122,997,000 after acquiring an additional 1,854,238 shares during the period. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.